InsiderTrades.com logo
Iqbal J. Hussain net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Iqbal Hussain Biography and Net Worth

General Counsel and Corporate Secretary of Centessa Pharmaceuticals

Iqbal Hussain is General Counsel and Corporate Secretary of Centessa Pharmaceuticals and is responsible for the leadership of our legal, compliance, IP, and corporate functions.

Prior to joining Centessa, Iqbal served as a partner in the Global Corporate Group at Reed Smith, LLP, where he led the life sciences transactional practice across EMEA from September 2019 to January 2021.

Before joining Reed Smith, Iqbal was Legal Director for Mergers and Acquisitions at Johnson & Johnson. From February 2014 to August 2019, he was Senior Counsel and a member of the leadership team at the Johnson & Johnson EMEA Innovation Centre in London.

Iqbal began his career at Slaughter and May where he advised clients on public and private mergers and acquisitions. Iqbal was a senior associate in the Corporate Mergers and Acquisitions team at Ropes & Gray, LLP.

Iqbal received an LLB from the University of Sheffield in 2004.

What is Iqbal J. Hussain's net worth?

The estimated net worth of Iqbal J. Hussain is at least $1.30 million as of March 17th, 2025. Mr. Hussain owns 105,386 shares of Centessa Pharmaceuticals stock worth more than $1,296,248 as of April 18th. This net worth evaluation does not reflect any other assets that Mr. Hussain may own. Learn More about Iqbal J. Hussain's net worth.

How old is Iqbal J. Hussain?

Mr. Hussain is currently 43 years old. There are 6 older executives and no younger executives at Centessa Pharmaceuticals. The oldest executive at Centessa Pharmaceuticals is Dr. David M. Chao Ph.D., Chief Administrative Officer, who is 56 years old. Learn More on Iqbal J. Hussain's age.

How do I contact Iqbal J. Hussain?

The corporate mailing address for Mr. Hussain and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at investorrelations@centessa.com. Learn More on Iqbal J. Hussain's contact information.

Has Iqbal J. Hussain been buying or selling shares of Centessa Pharmaceuticals?

Iqbal J. Hussain has not been actively trading shares of Centessa Pharmaceuticals during the past quarter. Most recently, Iqbal J. Hussain sold 6,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $16.45, for a transaction totalling $98,700.00. Following the completion of the sale, the general counsel now directly owns 105,386 shares of the company's stock, valued at $1,733,599.70. Learn More on Iqbal J. Hussain's trading history.

Who are Centessa Pharmaceuticals' active insiders?

Centessa Pharmaceuticals' insider roster includes Karen Anderson (Chief People Officer), Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), David Grainger (Insider), Iqbal Hussain (General Counsel and Corporate Secretary), Aaron Kantoff (Director), Harris Rotman (Senior Vice President, Regulatory Affairs), Saurabh Saha (CEO), Gregory Weinhoff (Chief Business Officer), and Antoine Yver (EVP). Learn More on Centessa Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Centessa Pharmaceuticals?

In the last year, insiders at the sold shares 34 times. They sold a total of 916,683 shares worth more than $15,287,044.28. The most recent insider tranaction occured on March, 25th when insider Gregory M Weinhoff sold 10,000 shares worth more than $163,400.00. Insiders at Centessa Pharmaceuticals own 11.6% of the company. Learn More about insider trades at Centessa Pharmaceuticals.

Information on this page was last updated on 3/25/2025.

Iqbal J. Hussain Insider Trading History at Centessa Pharmaceuticals

See Full Table

Iqbal J. Hussain Buying and Selling Activity at Centessa Pharmaceuticals

This chart shows Iqbal J Hussain's buying and selling at Centessa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals logo
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Read More

Today's Range

Now: $12.30
Low: $11.87
High: $12.30

50 Day Range

MA: $14.94
Low: $10.71
High: $18.00

2 Week Range

Now: $12.30
Low: $7.75
High: $19.09

Volume

784,645 shs

Average Volume

604,999 shs

Market Capitalization

$1.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53